Scilex Holding Company Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
$0.74next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Net Product Revenue Annually30.3M
Cash and Cash Equivalents Quarterly3.4M
Watch Items
- Cash Runway and Financing NeedsTrigger: Cash balance falling below $15 millionAction: Evaluate dilutive equity offerings, debt restructuring, or strategic asset sales.
- Regulatory Approval of SEMDEXA (SP-102)Trigger: FDA feedback or clinical trial milestones on the second Phase 3 studyAction: Assess commercialization timeline and update valuation models.
Research as of 19 Jun 2026